Solexa Ltd., of Cambridge, UK, appointed Nick McCooke chief operating officer and Harold Swerdlow head of technology development.

Structural Bioinformatics Inc., of San Diego, added Ian McDonald as vice president of drug discovery.

Targeted Genetics Corp., of Seattle, appointed David Schubert president; Alan Hardwick senior director, process development; and David McMillen associate director, process development at its wholly owned subsidiary, CellExSys.

Targeted Genetics Corp., of Seattle, made numerous changes. It promoted Barrie Carter to chief scientific officer; Pervin Anklesaria to vice president, research; Morrey Atkinson to vice president, development; David Poston to senior director, finance; Susan Primrose to senior director, business development; Geoff Roach to senior director, human resources; Haim Burstein to director, product discovery; Dara Lockert to director, project management; and Ralph Paul to director, technology discovery. It also appointed Vaughn Himes to vice president, manufacturing and Richard Peluso to senior director, technology development.

Telik Inc., of South San Francisco, appointed Stephen Carter to its scientific advisory board.

Vertex Pharmaceuticals Inc., of Cambridge, Mass., promoted John Thomson to vice president, research, and Mark Murcko to chief technology officer and chair of the scientific advisory board.

ViaCell Inc., of Boston, appointed Roland Scollay and Kevin Wilson to its board.

ViroLogic Inc., of South San Francisco, appointed Karen Wilson as vice president and chief financial officer.